Eli Lilly and Company (NYSE:LLY) Trading 1.8% Higher - Here's Why

Key Points

• Commercial and strategic catalysts: Eli Lilly committed $500M to South Korea’s biotech sector and gained wider retail access to its Zepbound KwikPen via Amazon Pharmacy, supporting expansion of its weight‑management franchise and APAC R&D/partnering opportunities.
• Strong financials and bullish analyst view: The company beat Q results (EPS $7.54; revenue $19.29B, +42.6% YoY), provided FY2026 EPS guidance of 33.50–35.00, and retains a consensus "Moderate Buy" with an average price target of $1,229.59.
• Key near‑term risks: A certified nationwide class in Actos racketeering litigation, Medicare reimbursement uncertainty around the $50 cap for weight‑loss drugs, and concerns about a rich valuation could drive headline volatility and downside risk.

Eli Lilly and Company (NYSE:LLY - Get Free Report) was up 1.8% during trading on Monday . The stock traded as high as $1,008.93 and last traded at $1,008.4190. Approximately 2,797,338 shares changed hands during trading, a decline of 15% from the average daily volume of 3,284,525 shares. The stock had previously closed at $990.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly committed $500M to South Korea’s biotech sector, signaling accelerated R&D/partnering access and longer-term growth opportunities in APAC markets. Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why
• Positive Sentiment: Amazon Pharmacy expanded access to Lilly’s Zepbound KwikPen, improving patient convenience and potential uptake of its weight‑management franchise. Greater retail distribution tends to support sales growth. Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management
• Positive Sentiment: J.P. Morgan reaffirmed a buy rating on LLY, which supports investor confidence and can help buoy the stock amid mixed headlines. J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)
• Neutral Sentiment: Coverage noting AI’s role in healthcare cites leaders like Lilly as potential long-term beneficiaries of AI-driven drug discovery/efficiency, but this is a thematic tailwind rather than an immediate catalyst. 2 Top AI Healthcare Stocks to Buy and Hold
• Neutral Sentiment: Industry distribution moves (Novo selling via Hims & Hers) reshape competitive dynamics in obesity drugs; this mainly affects Novo but increases market access complexity for all players. Novo Nordisk to Sell Ozempic, Wegovy Through Hims & Hers; Drops Lawsuit
• Negative Sentiment: A U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to Actos, renewing legal and potential cash‑flow liabilities for Lilly related to older diabetes drugs. This raises downside risk and headline volatility. Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
• Negative Sentiment: Lilly warned some basic Medicare plans may not follow the intended $50/mo out‑of‑pocket cap for weight‑loss drugs under the new model, creating pricing/reimbursement uncertainty that could affect patient access and uptake. Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs
• Negative Sentiment: Multiple commentary pieces flag Lilly’s rich valuation relative to peers and growth expectations, which can pressure the stock if top‑line growth slows or guidance disappoints. Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Truist Financial restated a "buy" rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Barclays started coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 target price on the stock. Guggenheim boosted their price target on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a "buy" rating in a report on Thursday, February 26th. BMO Capital Markets restated an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $1,229.59.

Eli Lilly and Company Stock Up 1.8%

The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The business has a 50-day simple moving average of $1,045.63 and a 200-day simple moving average of $942.56. The company has a market cap of $951.30 billion, a PE ratio of 43.94, a P/E/G ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business's revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently modified their holdings of LLY. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Eli Lilly and Company by 19.0% during the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company's stock worth $109,291,000 after purchasing an additional 22,410 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock valued at $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $1,180,000. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.